As the global economy mends, the 2021 growth of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics will have significant change from previous year. According to our (LP Information) latest study, the global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market size is USD million in 2022 from USD 3428.8 million in 2021, with a change of % between 2021 and 2022. The global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market size will reach USD 4589.5 million in 2028, growing at a CAGR of 4.3% over the analysis period.
The United States Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market, reaching US$ million by the year 2028. As for the Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics players cover AbbVie, Allergan, Nordmark Arzneimittel, and Digestive Care, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
Therapeutics
Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning)
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
AbbVie
Allergan
Nordmark Arzneimittel
Digestive Care
Janssen Pharmaceuticals
Cilian
Anthera Pharmaceuticals
AzurRx Biopharma